European Firms Lack Confidence In China’s Intellectual Property Policy (China)
This article was originally published in PharmAsia News
A poll of European companies indicate they still are not confident recent changes in China's intellectual property-protection policies enhance the climate for doing business in the country. The firms polled showed less confidence than their American counterparts, citing continued intellectual property abuses and arbitrary Chinese laws. More than half said they did not plan to open research and development centers in the country because of that concern. They also complained about non-transparent government regulations as well as a stronger euro making ventures less profitable in China. (Click here for more - may require paid subscription
You may also be interested in...
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.